Bispecific Antibodies

Aug 24, 2026

Summary In August 2026, the FDA granted accelerated approval to Bristol Myers Squibb’s ZENBEXUS (iberdomide), the first-in-class CELMoD, in combination with daratumumab and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy. Approval rests on the Phase 3 EXCAL...

Jan 02, 2026

Delta-like Ligand 3 (DLL3) is rapidly establishing a position as one of the promising targets in the treatment of aggressive Neuroendocrine Cancers (NECs), including Small Cell Lung Cancer (SCLC), Neuroendocrine Prostate Cancer (NEPC), and Large-Cell Neuroendocrine Carcinoma (LCNEC), where existing treatments deliv...

Jun 10, 2025

Imagine a world where treatment options are as precise as a scalpel and as adaptable as a chameleon. Bispecific antibodies are paving the way for this future, bringing revolutionary advancements in oncology and various therapeutic fields. By harnessing the power of these dual-targeting agents, researchers are unloc...

Apr 02, 2025

Multiple myeloma, a complex blood cancer rooted in the bone marrow, affects 160K people globally each year, with a mortality rate of 106K. According to DelveInsight, nearly 75K new cases were reported across seven major markets in 2023, a figure expected to climb in the coming years. Yet, amid these sobering statis...

Mar 28, 2025

Non-small cell lung cancer (NSCLC) remains one of the toughest cancers to treat, but bispecific antibodies (BsAbs) are changing the game. Unlike traditional therapies, BsAbs are engineered to target two different antigens simultaneously, enhancing precision and boosting immune response. This dual-targeting approach...

Oct 04, 2024

Trispecific antibodies are the next frontier in targeted cancer therapy, offering a powerful new approach to treating complex diseases. These innovative antibodies are designed to bind to three different antigens simultaneously, enhancing treatment precision. By engaging multiple targets at once, trispecific antibo...